Biogen is deeply committed to transforming haemophilia management through innovative treatments. We have combined our long history of scientific and clinical excellence and our expertise in manufacturing large-scale biologics to develop and deliver clinically meaningful therapies. Biogen is the first company to provide prolonged circulating factor therapies for haemophilia A and haemophilia B. These therapies represent the first major advancements in haemophilia treatment in almost two decades and, following marketing authorisation approval, will be commercialised in Europe through our collaboration with Swedish Orphan Biovitrum AB (Sobi).

At Biogen, our commitment to the haemophilia community extends to supporting access to therapy, including humanitarian donations and providing comprehensive patient access and assistance programs shaped by community input.